TransMedics' Technology Poised To Transform Underpenetrated $8B Organ Transplant Market, Analyst Expects 22% Upside
TransMedics' Technology Poised To Transform Underpenetrated $8B Organ Transplant Market, Analyst Expects 22% Upside
Needham analyst initiated coverage on TransMedics Group Inc (NASDAQ:TMDX), a commercial-stage medical technology company focused on organ transplant therapy for end-stage organ failure patients across multiple disease states.
Needham分析師對TransMedics Group Inc (NASDAQ:TMDX)進行了初步涵蓋，該公司是一家專注於爲末期器官衰竭患者提供器官移植治療的商業階段醫療科技公司。
The company has developed the Organ Care System (OCS), which is designed to better preserve, assess, and maintain donor organs.
該公司開發了Organ Care System (OCS)，旨在更好地保存、評估和維護供體器官。
Needham notes that TransMedics' OCS technology, backed by extensive clinical data and multiple FDA approvals, is transforming the underpenetrated organ transplant market, which is over $8 billion and has less than 6% penetration.
Needham指出，TransMedics的OCS技術憑藉廣泛的臨床數據和多個FDA批准，正在改變滲透率低於6%的器官移植市場，該市場規模超過80億美元。
Also Read: This MedTech Company Has Market Expansion Opportunity, Says Bullish Analyst.
還閱讀：這家醫療科技公司有着市場擴張機會，看好分析師表示。
The company's National OCS Program (NOP), a turnkey organ procurement service, has been a significant growth driver.
該公司的National OCS Program (NOP)是一個一站式器官供應服務，已成爲重要的增長驅動因素。
TransMedics has its planes, a staff of surgeons and clinical specialists, and a logistics team that enables transplant centers to procure and transplant more organs.
TransMedics擁有自己的飛機、隊伍由外科醫生和臨床專家組成，以及一個物流團隊，使移植中心能夠採購和移植更多器官。
Needham notes that NOP is driving the increasing use of OCS, and TransMedics' revenue growth accelerated from 18% in 2021 before NOP to 209% in 2022 after NOP.
Needham指出，NOP推動了OCS的日益增多的使用，TransMedics的營業收入增長從NOP之前的2021年的18%加速到NOP之後的2022年的209%。
TransMedics is projected to become profitable in 2024, and operating margin, EPS, and cash flow are expected to improve rapidly in 2025-2026.
預計TransMedics將在2024年實現盈利，並且營業利潤率、每股收益和現金流量預計在2025-2026年有快速改善。
The analyst initiated with a Buy rating and a price target of $208, representing an upside of almost 22%, citing that the company is 'bending the organ transplant curve.'
分析師開始給予買入評級和208美元的目標價，表示漲幅接近22%，稱該公司正在「改變器官移植曲線」。
Needham writes, "We believe that TransMedics' valuation is reasonable considering its growth rate and potential for upside to consensus."
Needham寫道：「考慮到TransMedics的增長率和與共識的上漲潛力，我們認爲其估值是合理的。」
In the second quarter of 2024, revenue reached $114.3 million, a 118% year-over-year increase driven primarily by the increase in utilization of the Organ Care System across all three organs through the National OCS Program and additional revenue generated by the launch of TransMedics logistics services.
在2024年第二季度，營業收入達到1.143億元，同比增長118%，主要受到全國OCS計劃對三個器官的利用率提高以及TransMedics物流服務推出帶來的額外收入的推動。
Price Action: TMDX stock is up 2.58% at $170.47 at the last check on Wednesday.
股票價格：截至上週三，TMDX股票上漲2.58%，報170.47美元。
- Wegovy Now Available Through Sesame's $249 Monthly Compounded Program Despite Supply Shortages.
- 儘管供應不足，Wegovy現在可以通過Sesame的249美元每月複利計劃購買。